On December 14, 2023, Hasten Biopharmaceutical Co., Ltd announced that it will enter into a strategic business partnership with Apeloa Pharmaceutical Co., Ltd.

Summer XIA, CEO of Hasten said, “We are very pleased to form a strategic business partnership with Apeloa. Apeloa has outstanding pharmaceutical manufacture facilities, R&D capabilities, and quality control systems, which provide a good collaboration platform for the development of global innovative pharmaceutical companies. This cooperation will better help Hasten realize its corporate mission of 'providing high-quality medicines and solutions that improve lives of people and create social value’."

ZHU Fangmeng, Chairman of Apeloa, said, " As an innovative biopharmaceutical company focusing on cardiovascular and metabolic fields, Hasten demonstrates a highly professional in the field of biopharmaceuticals. We hope that both parties will take this cooperation as an opportunity to jointly explore deep and multi-faceted cooperation and work together to provide stable and effective drugs for Chinese patients with cardiovascular diseases."

On the same day, Summer XIA & Hanson ZHENG, Vice President and Head of Business Excellence Operations Department, and relevant leaders of Hasten visited Apeloa and met with ZHU Fangmeng, Assistant President of Hengdian Group and Chairman of Apeloa, as well as relevant leaders, and had in-depth discussions on CMO and CDMO related topics. Afterwards, Hasten's senior management team also visited the CDMO R&D Center and the exhibition hall of Apeloa, to gain a deeper understanding of the enterprise.

This strategic business cooperation is another milestone initiative after Hasten and LIB Therapeutic Inc. reached an alignment on Lerodalcibep, a third-generation long-acting PCSK9 inhibitor, an innovative drug under development in September this year, marking Hasten's efforts to construct the whole biopharmaceutical industry chain.